Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

"The most striking finding," said George M. Gill, MD, Oncolytic's Senior VP of Clinical and Regulatory Affairs, "is that in nine evaluable late-stage head and neck cancer patients, eight of whom have refractory disease, four had durable partial responses and four others showed stable disease for periods of two, five plus, and eight cycles."

Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response. These results appear to confirm preclinical evidence of synergy for REOLYSIN(R) and platinum/taxane combinations. A U.S. Phase 2 trial has now been opened in this patient population utilizing this regimen.

Fourteen patients have been treated to date in the Phase I and Phase II (REO 011) trials. The detailed results are summarized in the following table:

-------------------------------------------------------------------------

REOLYSIN

Primary Tumour Dose TCID(50) Cycles Best Response

-------------------------------------------------------------------------

Phase I patients

-------------------------------------------------------------------------

Melanoma 3x10(9) 2 PD

-------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... The following is an open letter sent April 30, 2015 ... (NYSE: CO ) from Jayhawk Capital. We ... China Cord Blood Corp (" China Cord ") will REJECT ... Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, a going ... Med and Mr. Kam, the Chairman of both China ...
(Date:4/30/2015)... Calif. , April 30, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Thursday, May 7, 2015 after the close of ... conference call and webcast on Thursday, May 7, 2015 ... discuss the results and recent corporate developments. ...
(Date:4/30/2015)... SAINT-MALO, FRANCE (PRWEB) April 30, 2015 ... States and at http://www.lespausa.com , Phytomer’s ... to sensitive and reactive skin while battling the ... inflammation. This restorative cream is formulated with star ... derived via biotechnology in a complex of soothing ...
(Date:4/29/2015)... (PRWEB) April 30, 2015 According ... Equipment Market by Product (Portable & Non-Portable), Component ... Defense, Automotive, Chemical, Metal & Mining, & Others), ... total market is expected to reach $1,453.76 Million ... Browse 71 market data tables and 92 figures ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... LaserGen, Inc., a DNA sequencing technology company, announced ... make an equity investment in the company. Prompting ... commercialize its novel reversible terminator chemistry, Lightning ... anticipates bringing its chemistry as reagent kits to ...
... Inc. announced today that it has entered into ... NYSE: SNY ), providing the global ... platform for the research, development and commercialization of ... (ADCC). "We are extremely pleased about our partnership ...
... German . , Leipzig: Research and industry ... as their application in research, medical diagnosis and treatment, ... for use in environmental analysis because their characteristics enable ... as a key fits a lock. In a new ...
Cached Biology Technology:SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM) 2BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis 2Fitting pieces for biosensors 2Fitting pieces for biosensors 3Fitting pieces for biosensors 4
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... in determining a leaf,s venation pattern, according to ... the open-access journal PLoS Computational Biology. The researchers ... of venation patterns, based on the assumption that ... These distortions appear due to the elastic stresses ...
... dramatic improvement in cheap solar cells now being developed in ... clumped into much larger porous spheres researchers at the ... than double the efficiency of converting solar energy to electricity. ... the national meeting of the American Chemical Society. ...
... Professor John Bell said QUT had worked with a Canberra-based ... as both windows and energy generators in houses or commercial ... a significant difference to home and building owners energy costs ... stored on onsold. Professor Bell said the glass was ...
Cached Biology News:Popcorn-ball design doubles efficiency of dye-sensitized solar cells 2
...
Human Cystatin A MAb (Clone 224705)...
... Molecular Probes is pleased to offer ... the ultrasensitive detection of primary amines. ... Indiana University, the ATTO-TAG reagents are ... (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all ...
...
Biology Products: